期刊论文详细信息
Vaccines
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
Christoph Andreas Fux1  Barbara Jakopp1  Arkady Ovchinnikov2  Oliver Findling2  Krassen Nedeltchev2  Lutz Achtnichts2  Johann Sellner3  Michael Oberle4 
[1] Department of Infectious Diseases and Hospital Infection Prevention, Aarau Cantonal Hospital, 5000 Aarau, Switzerland;Department of Neurology, Aarau Cantonal Hospital, 5000 Aarau, Switzerland;Department of Neurology, Landesklinikum Mistelbach-Gänserndorf, 2130 Mistelbach, Austria;Institute for Laboratory Medicine, Aarau Cantonal Hospital, 5000 Aarau, Switzerland;
关键词: SARS-CoV-2;    S1PR-modulator;    fingolimod;    humoral immune response;    vaccination;    COVID-19;   
DOI  :  10.3390/vaccines10020341
来源: DOAJ
【 摘 要 】

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次